1
|
Guo Q, Li X, Cui MN, Sun JL, Ji HY, Ni BB, Yan MX. CD13: A Key Player in Multidrug Resistance in Cancer Chemotherapy. Oncol Res 2020; 28:533-540. [PMID: 32532363 PMCID: PMC7751223 DOI: 10.3727/096504020x15919605976853] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
Cancer is one of the most serious diseases that are harmful to human health. Systemic chemotherapy is an optimal therapeutic strategy for the treatment of cancer, but great difficulty has been encountered in its administration in the form of multidrug resistance (MDR). As an enzyme on the outer cell surface, CD13 is documented to be involved in the MDR development of tumor cells. In this review, we will focus on the role of CD13 in MDR generation based on the current evidence.
Collapse
Affiliation(s)
- Qie Guo
- Department of Clinical Pharmacy, The Affiliated Hospital of Qingdao UniversityQingdao, ShandongP.R. China
| | - Xiao Li
- Department of Clinical Pharmacy, The Affiliated Hospital of Qingdao UniversityQingdao, ShandongP.R. China
| | - Meng-Na Cui
- Department of Clinical Pharmacy, The Affiliated Hospital of Qingdao UniversityQingdao, ShandongP.R. China
| | - Jia-Lin Sun
- Department of Clinical Pharmacy, The Affiliated Hospital of Qingdao UniversityQingdao, ShandongP.R. China
| | - Hong-Yan Ji
- Department of Clinical Pharmacy, The Affiliated Hospital of Qingdao UniversityQingdao, ShandongP.R. China
| | - Bei-Bei Ni
- Department of Clinical Pharmacy, The Affiliated Hospital of Qingdao UniversityQingdao, ShandongP.R. China
| | - Mei-Xing Yan
- Department of Pharmacy, Qingdao Women and Childrens HospitalQingdao, ShandongP.R. China
| |
Collapse
|
2
|
Protein Kinases C-Mediated Regulations of Drug Transporter Activity, Localization and Expression. Int J Mol Sci 2017; 18:ijms18040764. [PMID: 28375174 PMCID: PMC5412348 DOI: 10.3390/ijms18040764] [Citation(s) in RCA: 31] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2017] [Revised: 03/25/2017] [Accepted: 03/27/2017] [Indexed: 01/05/2023] Open
Abstract
Drug transporters are now recognized as major actors in pharmacokinetics, involved notably in drug–drug interactions and drug adverse effects. Factors that govern their activity, localization and expression are therefore important to consider. In the present review, the implications of protein kinases C (PKCs) in transporter regulations are summarized and discussed. Both solute carrier (SLC) and ATP-binding cassette (ABC) drug transporters can be regulated by PKCs-related signaling pathways. PKCs thus target activity, membrane localization and/or expression level of major influx and efflux drug transporters, in various normal and pathological types of cells and tissues, often in a PKC isoform-specific manner. PKCs are notably implicated in membrane insertion of bile acid transporters in liver and, in this way, are thought to contribute to cholestatic or choleretic effects of endogenous compounds or drugs. The exact clinical relevance of PKCs-related regulation of drug transporters in terms of drug resistance, pharmacokinetics, drug–drug interactions and drug toxicity remains however to be precisely determined. This issue is likely important to consider in the context of the development of new drugs targeting PKCs-mediated signaling pathways, for treating notably cancers, diabetes or psychiatric disorders.
Collapse
|
3
|
Li Y, Huang L, Sun J, Wei X, Wen J, Zhong G, Huang M, Bi H. Mulberroside A suppresses PXR-mediated transactivation and gene expression of P-gp in LS174T cells. J Biochem Mol Toxicol 2016; 31. [DOI: 10.1002/jbt.21884] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2016] [Revised: 11/01/2016] [Accepted: 11/11/2016] [Indexed: 11/05/2022]
Affiliation(s)
- Yuhua Li
- Department of Pharmacy; The First Affiliated Hospital of Nanchang University; Nanchang 330006 People's Republic of China
- Laboratory of Drug Metabolism and Pharmacokinetics, School of Pharmaceutical Sciences; Sun Yat-sen University; Guangzhou 510006 People's Republic of China
| | - Ling Huang
- School of Pharmaceutical Sciences; Hainan Medical University; Haikou 571199 People's Republic of China
| | - Jiahong Sun
- Laboratory of Drug Metabolism and Pharmacokinetics, School of Pharmaceutical Sciences; Sun Yat-sen University; Guangzhou 510006 People's Republic of China
| | - Xiaohua Wei
- Department of Pharmacy; The First Affiliated Hospital of Nanchang University; Nanchang 330006 People's Republic of China
| | - Jinhua Wen
- Department of Pharmacy; The First Affiliated Hospital of Nanchang University; Nanchang 330006 People's Republic of China
| | - Guoping Zhong
- Laboratory of Drug Metabolism and Pharmacokinetics, School of Pharmaceutical Sciences; Sun Yat-sen University; Guangzhou 510006 People's Republic of China
| | - Min Huang
- Laboratory of Drug Metabolism and Pharmacokinetics, School of Pharmaceutical Sciences; Sun Yat-sen University; Guangzhou 510006 People's Republic of China
| | - Huichang Bi
- Laboratory of Drug Metabolism and Pharmacokinetics, School of Pharmaceutical Sciences; Sun Yat-sen University; Guangzhou 510006 People's Republic of China
| |
Collapse
|
4
|
Carnicelli V, Lizzi AR, Gualtieri G, Bozzi A, Franceschini N, Di Giulio A. Effects of azidothymidine on protein kinase C activity and expression in erythroleukemic cell K562 and acute lymphoblastic leukemia cell HSB-2. Acta Biochim Biophys Sin (Shanghai) 2015; 47:278-84. [PMID: 25693686 DOI: 10.1093/abbs/gmv003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Azidothymidine (AZT) is one of the anti-retroviral drugs currently used for the treatment of HIV-infected patients. Several other effects of the drug have been studied in vitro, such as the alterations of some enzymes, the inhibition of cell proliferation, and the increase of transferrin receptor expression. In this study, we investigated the alterations of protein kinase C (PKC) activity, PKCα and PKCβII expressions and plasmatic membrane fluidity induced by AZT in two cancer cell lines, human chronic myeloid (K562) and human acute lymphoblastic (HSB-2) leukemia cells, respectively. The results showed that both PKC activity and membrane fluidity in HSB-2 cells increased after 24 h of drug incubation. PKCα expression in HSB-2 cells decreased after 48 h of AZT exposure, when the cell growth also decreased. However, in K562 cells, the PKCα and PKCβII expressions enhanced in the presence of the drug when the growth was inhibited. The results indicate that AZT is less effective in inhibiting the growth of acute lymphoblastic HSB-2 leukemia cells than inhibiting that of chronic myeloid K562 cells. In fact, after 24 h exposure, the HSB-2 cell growth decreased less than K562 cell growth.
Collapse
Affiliation(s)
- Veronica Carnicelli
- Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila I-67100, Italy
| | - Anna Rita Lizzi
- Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila I-67100, Italy
| | - Giancaterino Gualtieri
- Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila I-67100, Italy
| | - Argante Bozzi
- Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila I-67100, Italy
| | - Nicola Franceschini
- Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila I-67100, Italy
| | - Antonio Di Giulio
- Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila I-67100, Italy
| |
Collapse
|
5
|
Miklos W, Pelivan K, Kowol CR, Pirker C, Dornetshuber-Fleiss R, Spitzwieser M, Englinger B, van Schoonhoven S, Cichna-Markl M, Koellensperger G, Keppler BK, Berger W, Heffeter P. Triapine-mediated ABCB1 induction via PKC induces widespread therapy unresponsiveness but is not underlying acquired triapine resistance. Cancer Lett 2015; 361:112-20. [PMID: 25749419 DOI: 10.1016/j.canlet.2015.02.049] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2014] [Revised: 02/26/2015] [Accepted: 02/26/2015] [Indexed: 10/23/2022]
Abstract
Although triapine is promising for treatment of advanced leukemia, it failed against solid tumors due to widely unknown reasons. To address this issue, a new triapine-resistant cell line (SW480/tria) was generated by drug selection and investigated in this study. Notably, SW480/tria cells displayed broad cross-resistance against several known ABCB1 substrates due to high ABCB1 levels (induced by promoter hypomethylation). However, ABCB1 inhibition did not re-sensitize SW480/tria cells to triapine and subsequent analysis revealed that triapine is only a weak ABCB1 substrate without significant interaction with the ABCB1 transport function. Interestingly, in chemo-naive, parental SW480 cells short-time (24 h) treatment with triapine stimulated ABCB1 expression. These effects were based on activation of protein kinase C (PKC), a known response to cellular stress. In accordance, SW480/tria cells were characterized by elevated levels of PKC. Together, this led to the conclusion that increased ABCB1 expression is not the major mechanism of triapine resistance in SW480/tria cells. In contrast, increased ABCB1 expression was found to be a consequence of triapine stress-induced PKC activation. These data are especially of importance when considering the choice of chemotherapeutics for combination with triapine.
Collapse
Affiliation(s)
- W Miklos
- Department of Medicine I, Institute of Cancer Research and Comprehensive Cancer Center of the Medical University, Medical University of Vienna, Borschkegasse 8a, A-1090 Vienna, Austria
| | - K Pelivan
- Institute of Inorganic Chemistry, University of Vienna, Waehringer Str. 42, A-1090 Vienna, Austria; Research Platform "Translational Cancer Therapy Research", Vienna, Austria
| | - C R Kowol
- Institute of Inorganic Chemistry, University of Vienna, Waehringer Str. 42, A-1090 Vienna, Austria; Research Platform "Translational Cancer Therapy Research", Vienna, Austria
| | - C Pirker
- Department of Medicine I, Institute of Cancer Research and Comprehensive Cancer Center of the Medical University, Medical University of Vienna, Borschkegasse 8a, A-1090 Vienna, Austria
| | - R Dornetshuber-Fleiss
- Department of Medicine I, Institute of Cancer Research and Comprehensive Cancer Center of the Medical University, Medical University of Vienna, Borschkegasse 8a, A-1090 Vienna, Austria; Department of Pharmacology and Toxicology, University of Vienna, Althanstraße 14, A-1090 Vienna, Austria
| | - M Spitzwieser
- Department of Analytical Chemistry, University of Vienna, Waehringer Str. 38, A-1090 Vienna, Austria
| | - B Englinger
- Department of Medicine I, Institute of Cancer Research and Comprehensive Cancer Center of the Medical University, Medical University of Vienna, Borschkegasse 8a, A-1090 Vienna, Austria
| | - S van Schoonhoven
- Department of Medicine I, Institute of Cancer Research and Comprehensive Cancer Center of the Medical University, Medical University of Vienna, Borschkegasse 8a, A-1090 Vienna, Austria
| | - M Cichna-Markl
- Department of Analytical Chemistry, University of Vienna, Waehringer Str. 38, A-1090 Vienna, Austria
| | - G Koellensperger
- Department of Analytical Chemistry, University of Vienna, Waehringer Str. 38, A-1090 Vienna, Austria
| | - B K Keppler
- Institute of Inorganic Chemistry, University of Vienna, Waehringer Str. 42, A-1090 Vienna, Austria; Research Platform "Translational Cancer Therapy Research", Vienna, Austria
| | - W Berger
- Department of Medicine I, Institute of Cancer Research and Comprehensive Cancer Center of the Medical University, Medical University of Vienna, Borschkegasse 8a, A-1090 Vienna, Austria; Research Platform "Translational Cancer Therapy Research", Vienna, Austria
| | - P Heffeter
- Department of Medicine I, Institute of Cancer Research and Comprehensive Cancer Center of the Medical University, Medical University of Vienna, Borschkegasse 8a, A-1090 Vienna, Austria; Research Platform "Translational Cancer Therapy Research", Vienna, Austria.
| |
Collapse
|